Ironwood Pharmaceuticals Inc. (IRWD)
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact.
Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due
Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in total revenues in 2026 but faces 2027 Medicare price cuts and 2029 generic entry. Apraglutide's Phase 3 confirmatory trial launches in 2026, but competitive and regulatory hurdles cloud its $700m peak sales potential.
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?
Ironwood slides 14% in a month on weak Linzess Q4 sales, but strong demand, partnerships, and an upbeat 2026 outlook raise investor optimism.
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks
Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.
